Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Stereotactic Radiosurgery

Research Leaders

8 sponsors active, led by Memorial Sloan Kettering Cancer Center

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Phase 1 (2)
Phase 2 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT00587964Phase 2Completed

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

NCT00581815Phase 1Completed

Spectroscopy With Surface Coils and Decoupling

NCT00588276Phase 1Completed

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors

Showing all 3 trials

Research Network

Common Treatments

  • Stereotactic Radiosurgery1
  • 124iiodoazomycin Galactopyranoside1
  • 1h Spectroscopy At 15t And 3t1
  • Protondecoupled 31p Mrs At 15t1

Active Sponsors

  • Memorial Sloan Kettering Cancer Center3
  • Columbia University1
  • University of Pennsylvania1
  • Weill Medical College of Cornell University1
  • St. George's Hospital, London1

Top Investigators

Related Conditions

  • Colon Cancer2
  • Cervical Cancer2
  • Pancreatic Cancer2
  • Lung Cancer2
  • Rectal Cancer2

Activity Timeline